Upstate Active Clinical Trials
Study Title:(CA180372) A Phase II Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
What is the purpose of the study?Treatment study to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
Upstate Institutional Review Board (IRB) Number:276417
Patient Age Group:Children
Principal Investigator:Karol H Kerr, MD
Who can I contact for more information?
Name: Beatriz Kovar